Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short-term Investments (2022 - 2025)

Summit Therapeutics' Short-term Investments history spans 4 years, with the latest figure at $319000.0 for Q2 2025.

  • For Q2 2025, Short-term Investments changed 0.31% year-over-year to $319000.0; the TTM value through Jun 2025 reached $319000.0, changed 0.31%, while the annual FY2024 figure was $325000.0, N/A changed from the prior year.
  • Short-term Investments reached $319000.0 in Q2 2025 per SMMT's latest filing, roughly flat from $318000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $300.0 million in Q4 2022 to a low of $317000.0 in Q1 2024.
  • Average Short-term Investments over 4 years is $82.1 million, with a median of $324000.0 recorded in 2024.
  • Peak YoY movement for Short-term Investments: crashed 99.82% in 2024, then rose 0.32% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $300.0 million in 2022, then plummeted by 41.62% to $175.2 million in 2023, then plummeted by 99.81% to $325000.0 in 2024, then decreased by 1.85% to $319000.0 in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Short-term Investments are $319000.0 (Q2 2025), $318000.0 (Q1 2025), and $325000.0 (Q4 2024).